SpringWorks Therapeutics' (SWTX.O) drug for treating adult patients with a type of rare non-cancerous soft-tissue tumor will be sold in the U.S. at a list price of $29,000 for a 30-day supply, the company said on a conference call on Tuesday
https://www.reuters.com/business/healthcare-pharmaceuticals/springworks-non-cancerous-tumor-drug-be-priced-29000-per-month-us-2023-11-28/
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.